Product Registration in Brazil, API, DIFA and CADIFA

Register Products and Pharmaceutical Ingredients in Brazil with a Regulatory Strategy from Day One

Entering the Brazilian market takes much more than gathering documents. You need to understand the regulatory framework, map technical gaps, assess operational risks, organize evidence, and define a strategy fully aligned with ANVISA requirements. Kivalita speeds up your market entry with technical and legal confidence.

When to Hire Us: Who Is This For?

Strategic Guidance: Is Your Company Ready for the Brazilian Market?

If your operation is at one of the stages below, our regulatory consulting provides the right support to move your project forward:

  • International API Manufacturers: Foreign manufacturers that need to adapt their ingredients to Brazilian regulations.

  • Companies Seeking CADIFA: Organizations that need to obtain or maintain the Active Pharmaceutical Ingredient Dossier Adequacy Letter (CADIFA).

  • Brazilian and International Pharmaceutical Companies: Companies interested in registering and marketing new products and medicines in Brazil.

  • Distributors and Importers: Operations structuring their logistics and documentation chain under health regulation.

  • Feasibility Assessment: Companies that need to measure regulatory risks and feasibility before making major investments.

  • Local Regulatory Teams: In-house teams that need specialized technical support and an operational arm in Brazil.

How Kivalita Works: Our Method

End-to-End Regulatory Governance

We turn ANVISA’s complex submission process into a predictable path in 5 clear steps:

  1. Quick Regulatory Gap Analysis: A fast diagnosis to identify critical gaps in your current documentation.

  2. Regulatory Roadmap: A strategic timeline and the best regulatory pathway for your product.

  3. DIFA/CADIFA Submission Readiness: Careful preparation of the Active Pharmaceutical Ingredient Dossier (DIFA) for immediate submission.

  4. Technical Support and Responses: Agile consulting to draft technical responses to deficiency letters issued by the regulatory agency.

  5. Continuous K Post-Submission: Ongoing monitoring of regulatory developments and post-registration compliance.

Clear Project Deliverables

What Your Company Receives

Our commitment is to tangible evidence and high-level technical documentation that holds up in audits:

  • Customized regulatory requirements matrix
  • Report listing available and pending documents
  • Detailed map of technical and regulatory risks
  • Prioritized action plan to resolve bottlenecks
  • Regulatory roadmap with estimated timelines and technical milestones
  • Formal recommendation for the ANVISA submission strategy
  • On-site or remote support for technical and institutional meetings
  • Recurring monitoring and follow-up through the Continuous K system

Want to know if your documentation is ready for ANVISA?

Avoid commercial delays and rejections caused by documentation flaws. Run a structured Quick Regulatory Gap Analysis with our specialists and validate your project.

FAQ: Product Registration, API, DIFA and CADIFA

What is CADIFA and why does it matter for product registration in Brazil?

CADIFA (Active Pharmaceutical Ingredient Dossier Adequacy Letter) is the document issued by ANVISA certifying that the ingredient dossier (DIFA) fully meets the technical and Good Manufacturing Practice (GMP) requirements. It matters because it centralizes the evaluation of the active ingredient. Once a manufacturer obtains CADIFA, that ingredient can be linked to multiple medicine registrations in Brazil much faster, speeding up the launch of new products in the national market.

The terms are related, but they represent different concepts in ingredient regulation:

  • API (IFA in Portuguese): The Active Pharmaceutical Ingredient itself, the chemical substance responsible for the therapeutic effect.
  • DIFA: The Active Pharmaceutical Ingredient Dossier, the set of technical data, tests, analytical methods and manufacturing information for the ingredient submitted to ANVISA.
  • CADIFA: The official approval letter issued by ANVISA after successful technical review and validation of the DIFA.

Kivalita’s Quick Regulatory Gap Analysis is a fast diagnosis focused on identifying gaps, missing documents and technical inconsistencies before the official dossier submission. By anticipating framework issues or missing analytical evidence required by ANVISA, we sharply reduce the risk of lengthy regulatory deficiency letters or rejection, saving months of fees and valuable commercial windows.

Yes. ANVISA requires the technical and legal interface for regulatory processes and submissions to be handled locally. With Kivalita’s specialized support and Regulatory Roadmap, international API manufacturers have a senior technical team working directly in Brazil to answer agency questions promptly, organize complex documentation and support GMP inspections.

The regulatory journey does not end at filing. After submission, ANVISA may issue technical deficiency letters with short response deadlines. The Continuous K ecosystem monitors the process after submission and follows its developments. Our team helps structure technical responses, tracks regulatory updates and keeps your product’s status safe and compliant even after registration is granted.

Product Registration in Brazil - API - DIFA - CADIFA

We have extensive experience delivering solutions for pharmaceutical, food, cosmetics, sanitizing products and veterinary industries.

By submitting my information, I agree to the Privacy Policy.
Hello! Fill in the fields below to start a conversation on WhatsApp
By providing my data, I agree to the Privacy policies